{
    "ticker": "AKTX",
    "name": "Akari Therapeutics, Plc",
    "description": "Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of rare and autoimmune diseases. The company was founded in 2014 and is headquartered in London, UK. Akari is known for its innovative approach to targeting the complement system, a part of the immune system that can contribute to the pathogenesis of various diseases. Its lead product candidate, nomacopan, is a dual inhibitor of complement and leukotriene systems, designed to treat conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and other inflammatory diseases. The company is engaged in advancing its clinical trials and has shown promising results in early studies, which highlight the potential of nomacopan to provide significant benefits to patients suffering from debilitating conditions. Akari's mission is to harness the power of its proprietary drug development platform to deliver transformative therapies that improve patient outcomes. With a dedicated team of scientists and industry professionals, Akari is committed to addressing unmet medical needs and advancing the field of immunology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "London, UK",
    "founded": "2014",
    "website": "https://www.akaritx.com",
    "ceo": "Dr. David A. Horn",
    "social_media": {
        "twitter": "https://twitter.com/AkariThera",
        "linkedin": "https://www.linkedin.com/company/akari-therapeutics/"
    },
    "investor_relations": "https://www.akaritx.com/investors",
    "key_executives": [
        {
            "name": "Dr. David A. Horn",
            "position": "CEO"
        },
        {
            "name": "Dr. Mark Brender",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Nomacopan"
            ]
        }
    ],
    "seo": {
        "meta_title": "Akari Therapeutics, Plc | Innovative Biopharmaceuticals",
        "meta_description": "Explore Akari Therapeutics, Plc, a leader in developing novel therapeutics for rare and autoimmune diseases. Learn about their innovative approaches and product candidates.",
        "keywords": [
            "Akari Therapeutics",
            "Biopharmaceuticals",
            "Immunology",
            "Nomacopan",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What is Akari Therapeutics known for?",
            "answer": "Akari Therapeutics is known for developing innovative therapies targeting rare and autoimmune diseases, particularly through its lead product candidate, nomacopan."
        },
        {
            "question": "Who is the CEO of Akari Therapeutics?",
            "answer": "Dr. David A. Horn is the CEO of Akari Therapeutics, Plc."
        },
        {
            "question": "Where is Akari Therapeutics headquartered?",
            "answer": "Akari Therapeutics is headquartered in London, UK."
        },
        {
            "question": "What is the main product of Akari Therapeutics?",
            "answer": "The main product of Akari Therapeutics is nomacopan, which is designed to treat rare and autoimmune diseases."
        },
        {
            "question": "When was Akari Therapeutics founded?",
            "answer": "Akari Therapeutics was founded in 2014."
        }
    ],
    "competitors": [
        "PTCT",
        "ALNY",
        "GNMK"
    ],
    "related_stocks": [
        "BMY",
        "AMGN",
        "REGN",
        "VRTX"
    ]
}